AOTMiT: Transparency Council on lung cancer, palliative and hospice care, among others

Agenda:

1. Preparation of a position paper on the evaluation of the drug Givlaari (givosiranum) under the drug program B.128.FM.
   "Treatment of patients with acute hepatic porphyria (AHP) in adults and adolescents aged 12 years and older (ICD-10: E80.2)".
2. Preparation of an opinion on the appropriateness of covering medical devices with reimbursement:
   
   • disposable negative pressure wound therapy (NPWT) systems,
   • Contralateral signal transmission systems (CROS),
   • UVB comb lamp,
   • Baby breathing monitors with pulse oximeter,
   • picoflometers,
   • epileptic seizure detection system,
   • Shoulder blood pressure monitors that speak Polish,
   • thermometers that speak in Polish.

1. Prepare a position paper on changing the medical technology for the indications underlying the eligibility of adults for palliative and hospice care.
2. Preparation of a position paper on the evaluation of the drug Tevimbra (tislelizumabum) within the framework of the drug program B.6.
   "Treatment of patients with lung cancer (ICD-10: C34) and pleural mesothelioma (ICD-10: C45) - tislelizumab in first-line NDRP in combination with chemotherapy [RATIONALE 307 Study (BGB-A317-307)]".
3. Preparation of a position paper on the evaluation of the drug Tevimbra (tislelizumabum) within the framework of the drug program B.6.
   "Treatment of patients with lung cancer (ICD-10: C34) and pleural mesothelioma (ICD-10: C45) - tislelizumab in the next line of treatment [RATIONALE-303 study (BGB-A317-303)]".
4. Preparation of a position paper on the evaluation of the drug Tevimbra (tislelizumabum) within the framework of the drug program B.6.
   "Treatment of patients with lung cancer (ICD-10: C34) and pleural mesothelioma (ICD-10: C45) - tislelizumab in first-line NDRP in combination with chemotherapy with PD-L1 ≥ 50% [RATIONALE-304 study (BGB-A317-304)]".

Source: AOTMiT